Open access · OA
via Europe PMC
Mitophagy as an active regulator of cardiac metabolic reprogramming.
Frontiers in cardiovascular medicine · 2026
Deregulated nutrient-sensing
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Disabled macroautophagy
Exercise
Partial reprogramming (OSK)
Human
Preclinical / animal
Review
Abstract
Mitophagy is increasingly recognized as a context-dependent regulator of cardiac metabolic adaptation rather than solely as a disposal pathway for damaged mitochondria. By coupling mitochondrial turnover to substrate selection, redox control, and inflammatory signaling, mitophagy can influence fatty acid oxidation (FAO), glycolysis, and oxidative phosphorylation (OXPHOS) in cardiomyocytes, vascular endothelial cells, and immune cells. In this review, the term Mitophagy-Metabolic Rewiring Axis (MMRA) is used as an integrative conceptual framework-not as a newly discovered pathway or theory-to organize evidence for bidirectional interactions between mitophagy and metabolic remodeling. The framework comprises stress inputs, mitophagy machinery and flux, metabolic outputs, and cell- or disease-level consequences, while emphasizing that the biological effect of mitophagy depends on cell type, disease stage, and duration of activation. We critically assess the AMP-activated protein kinase (AMPK)-UNC-51-like kinase 1 (ULK1), sirtuin 3 (SIRT3)-peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1<i>α</i>), PTEN-induced kinase 1 (PINK1)-Parkin E3 ubiquitin ligase, and hypoxia-inducible factor 1-alpha (HIF-1<i>α</i>)-BCL2-interacting protein 3 (BNIP3)/FUN14 domain-containing 1 (FUNDC1) modules in atherosclerosis, heart failure, and ischemia/reperfusion injury. Pharmacological, substrate-based, and exercise interventions are evaluated with particular attention to the predominantly preclinical evidence base, methodological limitations in measuring mitophagy flux, and the need for validated human biomarkers. Multi-omics and spatial approaches may improve mechanistic resolution, but clinical translation will require prospective studies that link target engagement to metabolic and cardiovascular outcomes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fcvm.2026.1884607
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
L, G., Y, L., C, Y., & M., W. (2026). Mitophagy as an active regulator of cardiac metabolic reprogramming. <em>Frontiers in cardiovascular medicine</em>. https://doi.org/10.3389/fcvm.2026.1884607
Vancouver
L G, Y L, C Y, M. W. Mitophagy as an active regulator of cardiac metabolic reprogramming. Frontiers in cardiovascular medicine. 2026. doi:10.3389/fcvm.2026.1884607.
BibTeX
@article{gai2026Mitoph,
title = {Mitophagy as an active regulator of cardiac metabolic reprogramming.},
author = {Gai L and Li Y and Yang C and Wang M.},
journal = {Frontiers in cardiovascular medicine},
year = {2026},
doi = {10.3389/fcvm.2026.1884607},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Cardiovascular Medicine 2026
Open access · CC-BY
Mitophagy as an active regulator of cardiac metabolic reprogramming
Bioactive Compounds in Health and Disease 2026
Open access · CC-BY
Food bioactives as modulators of autophagy and mitophagy ininflammaging and healthy aging
Journal of Molecular Medicine 2011
Open access · CC-BY
AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan
2025
Preprint · OA
Mitophagy in cardiovascular diseases: mechanisms and potential therapies
Cells 2026
Open access · OA
Mitochondrial Dysfunction as a Driver of Meta-Inflammation in Aging: The Emerging Role of PDK4 in Bioenergetic Reprogramming and Inflammatory Amplification.
Cells 2026
Open access · CC-BY